Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PRGO
HOLDPerrigo Company plc · Healthcare · Ireland · $1.4B · Avg Vol: $38M/d
COMPANY DESCRIPTION
Perrigo Company plc is a global consumer self-care company specializing in the development, manufacture, and marketing of over-the-counter (OTC) health and wellness products, including leading store brand and generic medicines. The company holds a dominant market position in the store brand OTC sector across the United States and Europe, leveraging its extensive manufacturing capabilities and deep retail partnerships. Perrigo's strategy focuses on providing affordable, high-quality self-care solutions to a broad consumer base.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.5B | 4.7B | 4.4B | 4.3B | -1.5% | 4.2B | 4.1B | 4.1B | -1.8% |
| EPS | -1.04 | -0.09 | -1.25 | -10.29 | — | -12.77 | — | — | — |
| Shares | 134.7M | 135.5M | 136.4M | 137.6M | +2.2% | 138.4M | — | — | — |
| Debt | 4.1B | 4.1B | 3.6B | 3.6B | -3.9% | 3.8B | — | — | — |
| Equity | 4.8B | 4.8B | 4.3B | 2.9B | -15.4% | — | — | — | — |
| Op CF | 307.3M | 405.5M | 362.9M | 238.5M | -8.1% | 189.4M | — | — | — |
| Inv CF | -2.0B | -77.5M | 78.8M | -75.4M | — | — | — | — | — |
| Fin CF | 421.6M | -187.2M | -611.0M | -220.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRGO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRGO | Perrigo Company plc(you) | $1.4B | 51 | HOLD |
| ALKS | Alkermes plc | $8.8B | 78 | BUY |
| UPR.L | Uniphar plc | $1.4B | 67 | BUY |
| GHRS | GH Research PLC | $1.9B | 34 | SELL |
| COPN.SW | Cosmo N.V. | $1.4B | 19 | STRONG SELL |
| AMRN | Amarin Corporation plc | $284M | 45 | HOLD |
| 0RGI.L | Cosmo Pharmaceuticals N.V. | $1.8B | 17 | STRONG SELL |
| PRTA | Prothena Corporation plc | $458M | 28 | SELL |
| ICLR | ICON Public Limited Company | $12.8B | 57 | HOLD |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 88 | STRONG BUY |
Peer medians: ROE 1.8% · P/E 23.4x · Gross margin 48.5%